- |||||||||| 5-fluorouracil / Generic mfg.
Journal, Cancer stem: Modeling 5-FU-Induced Chemotherapy Selection of a Drug-Resistant Cancer Stem Cell Subpopulation. (Pubmed Central) - Mar 27, 2024 (2) The expression of markers CD24, CD44, ALDH1, and ABCG2 was analyzed on the surface of CSCs in two cancer cell lines, MDA-MB-231 and HCT-116, after treatment with 5-fluorouracil (5-FU) using flow cytometry analysis...(4) Each individual GA prediction model achieved high accuracy in estimating the expression rate of CSC markers on cancer cells treated with 5-FU. Artificial intelligence can be used as a powerful tool for predicting drug resistance.
- |||||||||| 5-fluorouracil / Generic mfg., ibuprofen / Generic mfg.
Journal: pNIPAm-Based pH and Thermoresponsive Copolymer Hydrogel for Hydrophobic and Hydrophilic Drug Delivery. (Pubmed Central) - Mar 27, 2024 Moreover, the MTT assay and hemocompatibility analysis results proved that the pNIPAm-co-pGMA-Mela hydrogel system is biocompatible and hemocompatible, suggesting that that it could be used for drug delivery applications. The experimental results suggest that the proposed pNIPAm-co-pGMA-Mela hydrogel system is responsive to dual pH and temperature stimuli, and could be a promising drug carrier system for both hydrophilic and hydrophobic drug delivery applications.
- |||||||||| 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., irinotecan / Generic mfg.
Journal: Vascularized tissue on mesh-assisted platform (VT-MAP): a novel approach for diverse organoid size culture and tailored cancer drug response analysis. (Pubmed Central) - Mar 27, 2024 The PDX sample from a positive responder exhibited a significant reduction in cell viability across all organoid sizes when exposed to chemotherapeutic agents (5-FU, oxaliplatin, and irinotecan), as expected for cytotoxic drugs...Its capacity to handle various organoid sizes leads to results that more accurately reflect PDX models and differ markedly from traditional in vitro methods. The platform's distinct advantage lies in demonstrating how organoid size can critically influence drug response, revealing insights into cancer biology previously unattainable with conventional techniques.
- |||||||||| 5-fluorouracil / Generic mfg.
Biomarker, Journal, Tumor mutational burden, Tumor microenvironment, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker: Immune signature of small bowel adenocarcinoma and the role of tumor microenvironment. (Pubmed Central) - Mar 26, 2024 Treatment involves platinum-based chemotherapy with a 5-fluorouracil combination, but the lack of effective chemotherapy contributes to a generally poor prognosis...The presence of PD-L1 and programmed cell death 1, along with tumor-infiltrating lymphocytes, plays a crucial role in the complex microenvironment of SBA and contributes to a more favorable prognosis, especially in the context of high MSI tumors. Stromal tumor-infiltrating lymphocytes are identified as independent prognostic indicators and the association between MSI status and a favorable prognosis, emphasizes the importance of evaluating the immune status of tumors for treatment decisions.
- |||||||||| elesclomol (STA-4783) / Madrigal Pharma
Biomarker, Journal: Validation of CDC45 as a novel biomarker for diagnosis and prognosis of gastric cancer. (Pubmed Central) - Mar 26, 2024 Enrichment analysis revealed that CDC45 and its associated genes may play crucial roles in muscle biofunction, whereas GSEA demonstrated significant enrichment of gene sets pertaining to G protein-coupled receptor ligand binding and G alpha (i) signaling events. Our study elucidates that upregulation of CDC45 is intricately associated with immune cell infiltration and holds promising potential as a favorable prognostic marker and a novel diagnostic biomarker for GC.
- |||||||||| Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, HEOR, PD(L)-1 Biomarker, IO biomarker, Cost-effectiveness, Cost effectiveness, Metastases: Nivolumab plus ipilimumab versus the EXTREME regimen in recurrent/metastatic squamous cell carcinoma of the head and neck: a cost-effectiveness analysis. (Pubmed Central) - Mar 26, 2024 Importantly, there was heterogeneity in the cost-effectiveness probabilities, based on primary sites and expression levels of PD-L1. Therefore, tailored treatment based on individual patient and clinical characteristics, remains important, and may impact the cost-effectiveness of the regimens under study.
- |||||||||| 5-fluorouracil / Generic mfg.
Journal: Chemotherapy-induced pneumatosis intestinalis followed by hepatic portal venous gas. A case report. (Pubmed Central) - Mar 25, 2024 We report here, a patient with liver metastases from colorectal cancer who developed PI followed by HPVG after treatment with 5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6). Timely attention and management of gastrointestinal symptoms following chemotherapy are essential in the treatment of this type of patient.
- |||||||||| 5-fluorouracil / Generic mfg.
Journal: Anthracycline-based hepatic arterial infusion chemotherapy achieved 17 (Pubmed Central) - Mar 25, 2024 Depletion of CPNE7 attenuated the malignant proliferation of CRC cells and enhanced the chemosensitivity of CRC cells to 5-fluorouracil. A 46-year-old woman with estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer who had multiple LMs and bone metastases underwent seven lines of systemic therapy (paclitaxel/bevacizumab for 38
- |||||||||| Cejemly (sugemalimab) / CStone Pharma
Clinical, P3 data, Journal, Metastases: First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study. (Pubmed Central) - Mar 25, 2024 P3 All patients were randomized at 2:1 to receive either sugemalimab (an anti-PD-L1 antibody; 1,200?mg) or placebo every 3?weeks for up to 24?months, plus chemotherapy (cisplatin 80?mg?m-2 on day?1 plus 5-fluorouracil 800?mg?m-2?day-1 on days?1-4) every 3?weeks for up to six cycles. Sugemalimab plus chemotherapy significantly prolonged progression-free survival and overall survival in treatment-na
- |||||||||| Opdivo (nivolumab) / Ono Pharma, BMS
Journal, Surgery: A Case of Conversion Surgery for Stage ? ATP-Producing Gastric Cancer with Distant Metastasis (Pubmed Central) - Mar 22, 2024 After 2 courses of systemic chemotherapy FOLFOX/nivolumab, total gastrectomy, D2 node dissection, splenectomy pancreas tail resection, cholecystectomy, hepatic resection, partial transverse colon resection, partial jejunum resection, Roux-en-Y reconstruction...The pathological efficacy evaluation was Grade 1a in the primary tumor. The patient has been recurrence-free for 9 months since the initial diagnosis.
- |||||||||| 5-fluorouracil / Generic mfg.
Journal, Metastases: History and Perspective of Chemotherapy in Advanced Esophageal Cancer (Pubmed Central) - Mar 22, 2024 trials, although no randomized controlled trials were conducted...In addition, the KEYNOTE-590 trial and the CheckMate 648 trial showed that pembrolizumab plus CF therapy was superior to CF, and nivolumab plus CF therapy and nivolumab plus ipilimumab were superior to CF in advanced esophageal carcinoma...Immune checkpoint inhibitors had prolonged survival, but the results are still unsatisfactory, and CF therapy combined with immune checkpoint inhibitors and novel agents is being investigated. This article reviews the history of chemotherapy in advanced or recurrent esophageal cancer and discusses future prospects.
- |||||||||| 5-fluorouracil / Generic mfg.
Journal: Exploring Product Release from Yeast Cytosine Deaminase with Metadynamics. (Pubmed Central) - Mar 22, 2024 After conversion of the prodrug into the toxic chemotherapeutic drug, 5-fluorouracil (5-FU), the slow product release from the enzyme limits the overall catalytic efficiency of the enzyme/prodrug system...Next, we use infrequent metadynamics to estimate the unbiased release rate from Kramers time-dependent rate theory and find a favorable comparison to experiment with a slower rate of product release for the 5-FU system. Our work demonstrates how adaptive sampling methods can be used to study the protein-ligand unbinding process for engineering enzyme/prodrug systems and gives insights into the molecular mechanism of product release for the yCD/5-FU system.
- |||||||||| evorpacept (ALX148) / ALX Oncology
Trial completion date, Metastases: A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01) (clinicaltrials.gov) - Mar 22, 2024 P1, N=174, Active, not recruiting, Our work demonstrates how adaptive sampling methods can be used to study the protein-ligand unbinding process for engineering enzyme/prodrug systems and gives insights into the molecular mechanism of product release for the yCD/5-FU system. Trial completion date: Feb 2024 --> Dec 2024
- |||||||||| Enweida (envafolimab) / 3DMed, Alphamab, Tracon Pharma, Ascletis, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Metastases: CEIL: Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 21, 2024 P2, N=198, Recruiting, Our findings indicated that hnRNPA2B1 interacts with and stabilizes lncRNA NEAT1, which contribute to the maintenance of stemness property via Wnt/?-catenin pathway and exacerbate chemoresistance in GC. Active, not recruiting --> Recruiting
- |||||||||| Avastin (bevacizumab) / Roche
Journal: Bleeding and thrombotic events in bevacizumab-treated patients with colorectal cancer on novel oral anticoagulants and antiplatelet medications. (Pubmed Central) - Mar 21, 2024 Bevacizumab is a humanized monoclonal anti-VEGF antibody often given in combination with fluorouracil-based chemotherapy as therapy for metastatic colorectal cancer (mCRC)...21 patients were identified who received bevacizumab and either apixaban or rivaroxaban for mCRC treatment...No patient experienced adverse thrombotic events. Patients with mCRC treated with bevacizumab and apixaban with no history of aspirin use within three years have a relatively low risk of bleeding that warrants treatment discontinuation.
- |||||||||| oxaliplatin / Generic mfg.
Review, Journal, Metastases: Role of Oxaliplatin in the Neoadjuvant Concurrent Chemoradiotherapy in Locally Advanced Rectal Cancer: a Review of Evidence. (Pubmed Central) - Mar 21, 2024 We tried to define whether adding oxaliplatin to concurrent chemoradiation with excellent performance and high-risk features benefits some subpopulations. The available literature suggests that by adding oxaliplatin there are some benefits in enhancing response to neoadjuvant chemoradiotherapy, however, without any translated improvements in long-term outcomes including overall and disease-free survival.
- |||||||||| 5-fluorouracil / Generic mfg., capecitabine / Generic mfg.
Journal: Fluoropyrimidine Toxicity: the Hidden Secrets of DPYD. (Pubmed Central) - Mar 20, 2024 Additional post-translational DPD modifications, as well as DPD inhibition by other drugs, may explain a proportion of enzyme activity variability. Therefore, there is still a lot we can learn about the DPYD/DPD fluoropyrimidine-induced toxicity machinery.
- |||||||||| 5-fluorouracil / Generic mfg.
Journal: Nanocomposite Hydrogels Based on Poly(vinyl alcohol) and Carbon Nanotubes for NIR-Light Triggered Drug Delivery. (Pubmed Central) - Mar 18, 2024 Hydrophilic chemotherapeutic 5-fluorouracil (5-FU) and hydrophobic ibuprofen drugs were independently loaded into hydrogels, and the drug release profiles were obtained under passive and NIR-irradiation conditions...Appropriate concentrations of the nanocomposite hydrogel loaded with 5-FU produced cytotoxicity in cancer cells without affecting noncancerous cells. The overall properties of the MWCNT-f-containing hydrogel and its photothermal behavior make it an attractive material to promote the release of hydrophilic and hydrophobic drugs, depending on the treatment requirements.
|